|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A01N 43/04 | (2006.01) |
| A01N 63/00 | (2006.01) | ||
| A61K 31/70 | (2006.01) | ||
| A61K 48/00 | (2006.01) |
| (11) | Number of the document | 2136633 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08732358.0 |
| Date of filing the European patent application | 2008-03-17 | |
| (97) | Date of publication of the European application | 2009-12-30 |
| (45) | Date of publication and mention of the grant of the patent | 2015-10-28 |
| (46) | Date of publication of the claims translation | 2016-02-10 |
| (86) | Number | PCT/US2008/057257 |
| Date | 2008-03-17 |
| (87) | Number | WO 2008/113078 |
| Date | 2008-09-18 |
| (30) | Number | Date | Country code |
| 894932 P | 2007-03-15 | US |
| (72) |
KIRN, David, US
|
| (73) |
SillaJen Biotherapeutics, Inc.,
450 Sansome Street, Suite 650, San Francisco, CA 94111,
US
|
| (74) |
Liucija JANICKAITĖ,
Inpatra UAB, Šeškinės g. 59-53, LT-07162 Vilnius,
LT
|
| (54) | Onkolitinė vėžio terapija raupų virusu |
| ONCOLYTIC VACCINIA VIRUS CANCER THERAPY |
| Payment date | Validity (years) | Amount | |
| 2019-03-04 | 12 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2020-03-17 |